You are here

REVA to Present Fantom 24-Month Data at TCT 2017

SAN DIEGO, Oct. 23, 2017 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce the Company’s scheduled presentations during the upcoming Transcatheter Cardiovascular Therapeutics (“TCT”) Conference, being held October 29th through November 2nd in Denver, Colorado.

The Company will release new data on the Fantom® bioresorbable scaffold (“BRS”), the only bioresorbable scaffold made from Tyrocore™, REVA’s proprietary tyrosine-derived polymer designed specifically for vascular scaffold applications. 24-month data on a subset of patients from the FANTOM II clinical trial will be presented by trial investigator, Dr. Ricardo A. Costa, from Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil, and Dr. James B. Hermiller Jr., from the Heart Center of Indiana in Indianapolis, Indiana.

The complete schedule of REVA’s presentations is as follows:

Tuesday, October 31, 2017
10:18 a.m.
Moderated Posters 4
Exhibit Hall
Moderated Poster Session: New BRS
FANTOM II Trial: First Report on Initial 24 Month Outcomes
Presented by Dr. Ricardo A. Costa 
4:43 p.m.
Mile High Ballroom
Didactic Session:  BVS, Part 1 – Devices and Emerging Data
Fantom: A Radiopaque “Stent-Like” BRS with Improved Expansion Characteristics
Presented by Dr. James B. Hermiller, Jr.
Wednesday, November 1, 2017
10:00 to 11:00 a.m.
Exhibit Hall
Poster Presentation
12-month Angiographic and Clinical Follow-up of the Fantom Scaffold
Presented by Dr. Georgios Bouras

The clinical data presented at the conference will be available in the Investor Relations section of REVA’s website at following the presentations. The clinical results will also be lodged with the Australian Securities Exchange and filed with the US Securities and Exchange Commission.

About REVA
REVA is a medical device company located in San Diego, California, USA, that has developed and commercialized a proprietary drug-eluting bioresorbable scaffold, as an alternative to metal stents, to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption is intended to allow the return of natural movement and function of the artery. The Company’s Fantom® scaffold received European CE Marking on April 3, 2017. It is designed with thin struts while maintaining strength and distinct ease-of-use features including complete scaffold visibility under x-ray and expansion with one continuous inflation.

 United States Australia Australia
 Investor & Media Enquiries: Investor Enquiries: Media Enquiries:
 REVA Medical, Inc. Inteq Limited Buchan Consulting
 Cheryl Liberatore Kim Jacobs Rebecca Wilson
 Director, Communications +61 438 217 279 +61 3 9866 4722
 +1 858-966-3045 Andrew Cohen  
   +61 408 333 452  
Monday, October 23, 2017 - 19:39

More Headlines

New Algorithm Surveys Alterations in DNA and Millions of Points in the Human Genome
First Oral Drug Increases Activity of the Body’s Deficient Enzyme
Venous Thromboembolism and Other Risks to Be Evaluated in Postmarketing Studies
Researchers Recommend Increased Testing for Men
New Draft Guidance Seeks to Better Target Patient Needs
It’s All in How the Data Are Analyzed
Two Phase 3 Studies Met Endpoint of Complete Clearance of Lesions